|
|||||
|
|
||||||
Journal of Clinical Oncology, Vol 25, No 4 (February 1), 2007: pp. 424-430 © 2007 American Society of Clinical Oncology. DOI: 10.1200/JCO.2005.05.2597 Quality of Life in Operable Colon Cancer Patients Receiving Oral Compared With Intravenous Chemotherapy: Results From National Surgical Adjuvant Breast and Bowel Project Trial C-06
From the National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Pittsburgh, PA; University of British Columbia, Vancouver, BC, Canada; Schools of Medicine and Public Health and the Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA; University of Pittsburgh Medical Center Cancer Center at Magee-Women's Hospital, Pittsburgh, PA; and Allegheny General Hospital, Pittsburgh, PA Address reprint requests to Jacek Kopec, ARC, 895 West 10th Ave, Vancouver, BC, Canada V5Z 1L7; e-mail: jkopec{at}arthritisresearch.ca Purpose: We compared health-related quality of life (HRQL), symptoms, and convenience of care (COC) in patients with stage II/III carcinoma of the colon who received either oral uracil/ftorafur (UFT) plus leucovorin (LV) or standard intravenous (IV) fluorouracil (FU) plus LV as adjuvant chemotherapy. Patients and Methods: We measured HRQL with the Functional Assessment of Cancer Therapy–Colorectal (FACT-C) questionnaire, Short Form-36 Vitality Scale (SF-36), and a Quality of Life Rating Scale (QLRS) at baseline, once during chemotherapy, and at 1 year. We used the Symptom Distress Scale (SDS) and treatment-specific Symptom Checklist (SCL) to assess symptoms and a modified Burden of Care form to assess COC at baseline, on day 1 of each treatment cycle, and at 1 year. Repeated measures analyses controlling for demographic variables and baseline scores were used for statistical comparisons. Results: The study accrued 1,608 patients, 803 to the FU arm and 805 to the UFT arm. There were no differences between the arms in overall FACT-C scores, FACT-C scores within the subscales of colon-specific, physical, emotional, social, and functional health, or QLRS scores. Patients taking UFT reported substantially higher COC. Statistically significant but small differences were observed for SF-36, favoring FU, and for SDS and SCL, both favoring UFT. Conclusion: Patients perceive adjuvant treatment with UFT + LV as more convenient than standard IV treatment with FU + LV. Both regimens are well tolerated and do not differ in their impact on HRQL. Supported by Public Health Service Grants No. U10CA-12027, P-U10CA-37377, U10CA-69651, U10CA-69974 from the National Cancer Institute, Department of Health and Human Services; Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT; and Taiho Pharmaceutical Co, Lts, Tokyo, Japan. Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
|
|
|||||||||||
|
Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|